Urine Methylation Markers in UTUC

Abroad (travel likely)Recruiting

Conditions

Upper Tract Urothelial Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Duke University, Durham, North Carolina, United States
Contact: Study coordinator (Alireza Ghoreifinejadian, M.D.) · alireza.ghoreifi@duke.edu · 919-684-8111
Contact: Principal Investigator (Michael Abern, M.D.)
Alireza Ghoreifinejadian, M.D. (Sub-investigator)

Study leads

Michael Abern, MD
Principal Investigator
Duke University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer

Bladder Cancer · Urothelial Carcinoma (UC) · Hematuria

Abroad (travel likely)Recruiting

Oceanside, United States · San Diego, United States

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Urinary Bladder Cancer · Upper Tract Urothelial Cancer · Urothelial Cancer

Abroad (travel likely)RecruitingPHASE2

New Brunswick, United States

Single-Port RAS Using Da Vinci SP Surgical System for UTUC Patients

Upper Tract Urothelial Cancer

Abroad (travel likely)Recruiting

Taipei, Taiwan

DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable · Upper Tract Urothelial Cancer

Abroad (travel likely)RecruitingPHASE4

Rome, Italy